Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABOS | Acumen Pharmaceuticals, Inc.

Index- P/E- EPS (ttm)-1.14 Insider Own7.83% Shs Outstand57.87M Perf Week-14.16%
Market Cap272.78M Forward P/E- EPS next Y-1.31 Insider Trans113.39% Shs Float53.12M Perf Month-26.78%
Income-46.50M PEG- EPS next Q-0.26 Inst Own77.20% Short Float / Ratio3.30% / 1.57 Perf Quarter-16.28%
Sales- P/S- EPS this Y79.00% Inst Trans4.38% Short Interest1.75M Perf Half Y15.93%
Book/sh4.12 P/B1.15 EPS next Y-21.30% ROA-24.30% Target Price15.57 Perf Year-4.25%
Cash/sh2.51 P/C1.88 EPS next 5Y9.70% ROE-25.40% 52W Range3.52 - 11.31 Perf YTD-12.41%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-58.18% Beta-1.10
Dividend %- Quick Ratio17.50 Sales past 5Y- Gross Margin- 52W Low34.38% ATR0.32
Employees39 Current Ratio17.50 Sales Q/Q- Oper. Margin- RSI (14)23.29 Volatility5.24% 4.61%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.90% Profit Margin- Rel Volume0.18 Prev Close4.91
ShortableYes LT Debt/Eq0.00 EarningsAug 08 BMO Payout- Avg Volume1.12M Price4.73
Recom1.60 SMA20-18.40% SMA50-27.84% SMA200-13.17% Volume195,773 Change-3.67%
Date Action Analyst Rating Change Price Target Change
Jul-20-23Resumed BofA Securities Buy $9 → $14
May-18-23Initiated Cantor Fitzgerald Overweight $13
Jul-15-22Initiated BTIG Research Buy $15
Jun-30-22Initiated H.C. Wainwright Buy $15
Jan-21-22Upgrade BofA Securities Neutral → Buy $16 → $14
Jul-26-21Initiated UBS Buy $27
Jul-26-21Initiated Stifel Buy $27
Jul-26-21Initiated Credit Suisse Outperform $26
Jul-26-21Initiated BofA Securities Neutral $20
Sep-19-23 04:00PM
Sep-06-23 04:00PM
Aug-08-23 10:21PM
Aug-01-23 04:00PM
01:47PM Loading…
Jul-25-23 01:47PM
Jul-18-23 10:31PM
Jul-17-23 04:53PM
Jul-16-23 03:00AM
Jul-03-23 05:13PM
Jun-28-23 06:30AM
Jun-13-23 07:00AM
12:41PM Loading…
May-16-23 12:41PM
May-09-23 07:00AM
May-04-23 04:01PM
May-02-23 04:01PM
Apr-09-23 08:57AM
Mar-29-23 07:30AM
Mar-28-23 08:00AM
Mar-27-23 07:00AM
Mar-22-23 04:01PM
Mar-20-23 04:01PM
Mar-08-23 04:01PM
Feb-15-23 12:07PM
Feb-13-23 08:00AM
Jan-06-23 09:40AM
Jan-04-23 08:00AM
06:02AM Loading…
Dec-29-22 06:02AM
Nov-14-22 04:01PM
Nov-09-22 04:01PM
Nov-07-22 04:01PM
Nov-01-22 08:00AM
Oct-24-22 08:00AM
Sep-08-22 12:44PM
Aug-15-22 11:00PM
Aug-08-22 04:15PM
Aug-01-22 10:30AM
Jul-26-22 04:15PM
Jun-08-22 08:00AM
May-16-22 10:00PM
May-11-22 05:08PM
Apr-27-22 08:00AM
Apr-02-22 12:00AM
Apr-01-22 05:01PM
Mar-28-22 04:05PM
Mar-16-22 04:15PM
Dec-30-21 04:16AM
Nov-25-21 07:35AM
Nov-15-21 08:00AM
Nov-08-21 08:00AM
Nov-02-21 08:00AM
Oct-07-21 08:00AM
Oct-01-21 06:05AM
Aug-16-21 04:05PM
Jul-23-21 07:13PM
Jul-01-21 05:02PM
Jun-30-21 10:44PM
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ives Jeffrey L.DirectorAug 17Option Exercise0.7541,94931,51939,149Aug 18 06:31 PM
Ives Jeffrey L.DirectorAug 17Sale6.4941,949272,3340Aug 18 06:31 PM
RA CAPITAL MANAGEMENT, L.P.DirectorJul 21Buy7.755,161,29039,999,99813,043,179Jul 25 04:30 PM
Zuga MattCFO and Chief Business OfficerDec 29Option Exercise1.1950,00059,50076,187Jan 03 05:23 PM